Xience Xpedition drug-eluting stent gets CE mark


Abbott has announced that its Xience Xpedition Everolimus Eluting Coronary Stent System received CE mark for the treatment of coronary arterial disease. The company is launching the product immediately in CE mark countries.

Xience Xpedition features a new stent delivery system designed to optimise acute performance, particularly in challenging coronary anatomies. This drug-eluting stent is available with a broad range of indications, including use with a minimum duration of three months of dual anti-platelet therapy (DAPT).

“The extraordinary deliverability of the new Xience Xpedition drug-eluting stent system allows physicians to treat particularly complex coronary disease with great ease and confidence,” said Evald H Christiansen, interventional cardiologist, Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, who treated the first patient with Xience Xpedition. “Supported by robust clinical evidence from the SPIRIT family of trials, and with a broad range of indications, Xience Xpedition is an important advancement in drug-eluting stent technology.”

Xience Xpedition has indications to treat patients with complex disease such as diabetes, as well as an indication for a minimum duration of three months of DAPT. According to a company release, this indication represents an important advantage, as three months of DAPT is the shortest duration required for any major drug-eluting stent offered in Europe.

Long-term compliance to DAPT can be a challenge for patients and can lead to additional safety risks such as increased bleeding events. In addition, having a shorter DAPT duration after stent implantation may be beneficial in case a patient needs to interrupt or discontinue the medication prior to surgery or for other considerations.

“With Xience Xpedition’s excellent deliverability, broad size matrix and the option to discontinue or interrupt DAPT after three months, physicians in Europe now have a new, comprehensive offering to address the challenges of treating patients with complex coronary arterial disease,” said Charles A Simonton, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular.

Xience Xpedition is available in one of the broadest size matrices on the European market, with diameters ranging from 2.25mm to 4mm, including a unique 3.25mm diameter, and lengths from 8mm to 38mm.